Lockheed Martin (NYSE:LMT) shares climb 10.5% after free-cash-flow outlook boosted by reduced capex
24 July 2026
2 mins read

Lockheed Martin (NYSE:LMT) shares climb 10.5% after free-cash-flow outlook boosted by reduced capex

NEW YORK, July 24, 2026, 06:08 EDT

  • Shares finished Thursday at $568.59, rising 10.5%. The most recent premarket price was $568.63.
  • Lockheed Martin Corp LMT said the midpoint for 2026 free cash flow increased by $450 million, while planned capital expenditures declined by an equal amount.
  • Backlog hit a record $230.4 billion. New orders amounted to roughly 3.2 times the company’s quarterly revenue.

Shares of Lockheed Martin Corporation jumped 10.5% on Thursday as the company delivered better-than-expected quarterly results and lifted its outlook. The stock ended the session at $568.59, with trading volume more than double its usual level.

The key investment indicator is found within the cash-flow improvement. Lockheed increased its projected 2026 free-cash-flow midpoint by $450 million.

Operating cash flow was flat at the midpoint. The overall gain corresponded with a $450 million reduction in projected capital expenditures.

The difference is significant amid a major production increase. Short-term cash saw gains, while the underlying operating cash flow remained unchanged.

2026 guidanceApril rangeJuly rangeMidpoint change
Sales$77.50–$80.00 billion$79.75–$81.75 billionRise of $2.00 billion, or 2.5%
Cash from operations$9.15–$9.45 billion$9.20–$9.40 billionNo change
Capital spending$2.50–$2.80 billion$2.00–$2.40 billionDecrease of $450 million, or 17.0%
Free cash flow$6.50–$6.80 billion$7.00–$7.20 billionIncrease of $450 million, or 6.8%
Diluted EPS$29.35–$30.25$29.95–$30.65Gain of $0.50, or 1.7%

Early midpoint estimates are derived from company guidance. Free cash flow is a non-GAAP figure defined by the company.

Chief Financial Officer Evan Scott stated that the reduced capex was partly due to timing. According to Scott, a missile facility will initially be leased and acquired next year to optimize taxes. The $8 billion-to-$9 billion munitions pledge “is unchanged,” Scott said. Investing.com

Some cost reductions could be permanent. Partners are able to supply factory facilities and capital as Lockheed increases production. Scott noted a “real opportunity here for more partnerships to scale production faster, particularly in Europe.” Reuters

Demand remains strong. Lockheed secured $65 billion in orders compared to $20.1 billion in quarterly revenue, leading to an initial book-to-bill ratio of 3.2. The backlog stood at $230.4 billion, roughly 2.9 times its projected yearly sales.

Growth was led by Missiles and Fire Control. Revenue climbed 19% to $4.10 billion and operating profit advanced 24%. Increases in PAC-3, THAAD and Precision Strike Missile volumes supported the rise.

Group sales increased by 11% to $20.1 billion. Diluted EPS stood at $7.94. The updated sales range surpassed the analyst estimate of $79.14 billion. The same period last year reflected $1.6 billion in program losses and $169 million in additional charges.

RTX Corporation lifted its guidance on Thursday. The stock rose 7.7%, while Lockheed shares added 10.5%. RTX posted a 14% increase in sales and reported a backlog of $289 billion.

Regular U.S. trading was shut at 06:08 EDT Friday, while premarket trading remained active. Lockheed last traded at $568.63 at 06:03 EDT, little changed.

Lockheed shares declined 2.8% over the prior week based on closing prices, then climbed 11.8% from July 17 to Thursday. Trading volume on Thursday reached about 2.4 times the 65-day average.

A peer review session is set for next week. General Dynamics Corporation will announce its second-quarter earnings on Wednesday, July 29. Lockheed has no investor events scheduled on its calendar.

Risks: Some of the capex reduction will defer expenditures to 2027. Lockheed is ramping up output for 10 munitions lines and multiple aircraft projects. Technical benchmarks for classified programs remain demanding. A delay in these areas could erode the cash conversion rate that has been favored by investors.

Thursday’s rally reflected expectations of robust demand and improved short-term cash flow. The upcoming challenge is determining if reduced spending signals lasting efficiency rather than postponed capacity investments.

Iwona Majkowska is a financial markets journalist at TS2.tech, specializing in stocks, artificial intelligence and technology. A graduate of the Warsaw School of Economics, she previously worked in equity research and financial analysis before focusing on market reporting. Her daily coverage helps investors follow major developments across U.S. and global markets. Follow Iwona Majkowska on Google News.

Stock Market Today

  • Hims & Hers (NYSE:HIMS) Rises as FDA Panel Backs Peptide Use for Compounding Pharmacies
    July 24, 2026, 7:12 AM EDT. Shares of Hims & Hers (NYSE:HIMS) climbed 3.4% to $32.74 as four unapproved peptides received support from a U.S. advisory panel for pharmacy compounding, potentially opening a $440 million sales opportunity by 2027. This figure amounts to roughly 15% of Hims' estimated $2.9 billion revenue midpoint for 2026. The ultimate FDA decision could take up to a year, and uncertainty persists as the advisory backing is non-binding and safety data on these peptides remains limited.
Oracle Corporation (NYSE:ORCL) Stock Rises on $7 Billion Pentagon Deal as Contract Math Tempers Rally
Previous Story

Oracle Corporation (NYSE:ORCL) Stock Rises on $7 Billion Pentagon Deal as Contract Math Tempers Rally

SAP SE (ETR:SAP) shares rise 6% as cloud backlog surpasses expectations despite profit guidance cut
Next Story

SAP SE (ETR:SAP) shares rise 6% as cloud backlog surpasses expectations despite profit guidance cut